Drugs / TBC-MVA
TBC-MVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00053742 | Feb 2003 → Mar 2006 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBC-MVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00053742 ↗ |
| Known as | Modified Vaccinia Virus Ankara | “This study will test the safety of an experimental vaccine called modified vaccinia virus ankara (MVA)” NCT00053742 ↗ |
| Known as | MVA | “This study will test the safety of an experimental vaccine called modified vaccinia virus ankara (MVA)” NCT00053742 ↗ |
| Modality | Vaccine | “This study will test the safety of an experimental vaccine called modified vaccinia virus ankara (MVA)” NCT00053742 ↗ |
| Route | Intramuscular | “evaluating the safety of MVA administered by intramuscular (IM) injection at 10(8) PFU” NCT00053742 ↗ |